Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Yau, T. [1 ]
Meyer, T. [2 ]
Kelley, R. K. [3 ]
Mangeshkar, M. [4 ]
Cheng, A-L. [5 ]
El-Khoueiry, A. B. [6 ]
Abou-Alfa, G. K. [7 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Royal Free Hosp, Oncol, London, England
[3] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[4] Exelixis, Biostat, Alameda, CA USA
[5] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meyer, T.
    Kelley, R. K.
    Mangeshkar, M.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y.
    Merle, P.
    Park, J-W.
    Blanc, J-F.
    Lim, H. Y.
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30 : 257 - U138
  • [3] Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Parnis, F.
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Blanc, J. F.
    Lim, H-Y
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 180 - 181
  • [4] Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Blanc, J. F.
    Meyer, T.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Cicin, I.
    Chen, Y.
    Bolondi, L.
    Dadduzio, V.
    Baron, A.
    Lin, Z-Z.
    Adriani, J.
    Kelly, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 237 - 237
  • [5] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    El-Khoueiry, A. B.
    Meyer, T.
    Rimassa, L.
    Merle, P.
    Chan, S. L.
    Tran, A.
    Parnis, F.
    Tam, V. C.
    Cattan, S.
    Markby, D. W.
    Clary, D. O.
    Cheng, A-L.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Outcomes based on plasma biomarkers for the Phase III CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Zekry, A.
    Rimassa, L.
    Kelley, R.
    Meyer, T.
    Ryoo, B.
    Merle, P.
    Park, J.
    Blanc, J.
    Lim, H.
    Tran, A.
    Borgman-Hagey, A.
    Clary, D.
    Wang, E.
    Cheng, A.
    El-Khoueiry, A.
    Abou-Alfa, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 41 - 42
  • [7] Outcomes By Baseline Alpha-Fetoprotein (AFP) Levels in the Phase 3 Celestial Trial of Cabozantinib (C) Versus Placebo (P) in Previously Treated Advanced Hepatocellular Carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Meyer, Timothy
    Rimassa, Lorenza
    Merle, Philippe
    Chan, Stephen L.
    Tran, Albert
    Parnis, Francis
    Tam, Vincent C.
    Cattan, Stephane
    Markby, David W.
    Clary, Douglas O.
    Cheng, Ann-Lii
    Kelley, Robin Kate
    HEPATOLOGY, 2018, 68 : 533A - 534A
  • [8] Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Park, Joong-Won
    Blanc, Jean-Frederic
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Yau, Thomas Cheung
    Sen, Suvajit
    Markby, David W.
    Kaldate, Rajesh
    El-Khoueiry, Anthony B.
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Cheng, A-L.
    Meyer, T.
    Ryoo, B-Y.
    Park, J-W.
    Klumpen, H-J.
    Lim, H. Y.
    Kim, S.
    Knox, J.
    Patel, M.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Rimassa, Lorenza
    Cicin, Irfan
    Blanc, Jean-Frederic
    Klumpen, Heinz Josef
    Zagonel, Vittorina
    Tran, Albert
    Kim, Stefano Chong Hun
    Lin, Zhong-Zhe
    Tam, Vincent C.
    Hazra, Saswati
    Mangeshkar, Milan
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345